Vaccine-associated reduction in symptom severity among patients with influenza A/H3N2 disease

Robert G. Deiss, John C. Arnold, Wei Ju Chen, Sara Echols, Mary P. Fairchok, Christina Schofield, Patrick J. Danaher, Erin McDonough, Michelande Ridoré, Deepika Mor, Timothy H. Burgess, Eugene V. Millar

Research output: Contribution to journalArticle

Abstract

Background: The moderate level of protection conferred by influenza vaccines is well-known, but the vaccine's ability to attenuate symptom severity among vaccinated individuals (i.e., vaccine failures) has not been established. Methods: We enrolled otherwise healthy adults who presented with influenza-like illness (ILI) at five US military hospitals between 2009 and 2014. Influenza was diagnosed and subtyped by PCR. Individual and composite severity scores were compared between those who had vs. had not received the seasonal influenza vaccine >14 days prior to enrollment. Results: A total of 155 cases of influenza (A/H1N1, n= 69; A/H3N2, n= 66; A/untyped, n= 3; B, n= 17) were identified, of whom 111 (72%; A/H1N1, n= 44; A/H3N2, n= 52; A/untyped, n= 3; B, n= 12) had been vaccinated. Women were significantly less likely to be vaccinated than men (49% vs. 89%; p<. 0.01). In multivariate analysis, vaccinated individuals were significantly less likely to report a fever >101. °F (OR 0.24; 95% CI [0.10, 0.62]) and more likely to report myalgias (OR 3.31; 95% CI [1.22, 8.97]) than vaccinated individuals. Among patients with A/H3N2 infection, upper respiratory and total symptom severity scores were significantly lower for vaccinated patients during the first 2 days of illness, and differences in total symptom severity persisted over 7 days (p< 0.05 for all comparisons). Differences across additional symptom categories (lower respiratory and systemic) were also observed throughout 7 days of illness in bivariate analyses. Differences in symptom severity were not observed between vaccinated and unvaccinated participants with A/H1N1 infection. Conclusions: Among patients with A/H3N2 infection, receipt of seasonal influenza vaccine was associated with reduced symptom severity. Patient-centered discussion about the benefits of influenza vaccination should be expanded to include the possibility that the vaccine could attenuate symptoms.

Original languageEnglish (US)
Pages (from-to)7160-7167
Number of pages8
JournalVaccine
Volume33
Issue number51
DOIs
StatePublished - Dec 16 2015

Keywords

  • Influenza
  • Military
  • Severity
  • Vaccine

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Vaccine-associated reduction in symptom severity among patients with influenza A/H3N2 disease'. Together they form a unique fingerprint.

  • Cite this

    Deiss, R. G., Arnold, J. C., Chen, W. J., Echols, S., Fairchok, M. P., Schofield, C., Danaher, P. J., McDonough, E., Ridoré, M., Mor, D., Burgess, T. H., & Millar, E. V. (2015). Vaccine-associated reduction in symptom severity among patients with influenza A/H3N2 disease. Vaccine, 33(51), 7160-7167. https://doi.org/10.1016/j.vaccine.2015.11.004